|Bid||2.0200 x 800|
|Ask||2.6900 x 800|
|Day's Range||2.3600 - 2.6000|
|52 Week Range||1.4900 - 19.2100|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Gerri Henwood has been the CEO of Recro Pharma, Inc. (NASDAQ:REPH) since 2008, and this article will examine the...
Good morning, and thank you for joining us on today's conference call to discuss Recro's third-quarter 2020 financial results. Following prepared remarks today by Gerri and Ryan, we will open the call for questions. Before we begin our formal comments, I'll remind you that various remarks we make today constitute forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements related to our financial outlook.
Shares of Recro Pharma (NASDAQ:REPH) were unchanged after the company reported Q3 results.Quarterly Results Earnings per share increased 52.63% year over year to ($0.09), which beat the estimate of ($0.20).Revenue of $19,287,000 declined by 23.63% from the same period last year, which beat the estimate of $16,330,000.Guidance Recro Pharma hasn't issued any earnings guidance for the time being.Recro Pharma hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 09, 2020View more earnings on REPHTime: 08:00 AMET Webcast URL: https://edge.media-server.com/mmc/p/ej8f56o2Recent Stock Performance Company's 52-week high was at $19.21Company's 52-week low was at $1.49Price action over last quarter: down 50.00%Company Description Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Its product portfolio includes Ritalin LA; Focalin XR; Verelan PM, SR and Verapamil PM; Verapamil SR and Zohydro ER.See more from Benzinga * Click here for options trades from Benzinga * Stocks That Hit 52-Week Lows On Monday * Stocks That Hit 52-Week Lows On Friday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.